课题基金 / 基金详情

项目摘要

项目成果

Deborah Merke的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The investigational regimen of an antiandrogen (flutamide), an aromatase inhibitor (letrozole), and reduced hydrocortisone dose vs. conventional treatment was shown short-term (2 year) to normalize linear growth rate and bone maturation. A prospective long-term randomized parallel study to adult height of an antiandrogen (flutamide) and an aromatase inhibitor (letrozole), and reduced hydrocortisone dose vs. conventional treatment is being completed. Patients that dropped out or were lost to follow-up are now being contacted to return to the NIH Clinical Center in order to obtain an adult height measurement. In a separate study, Abiraterone, an irreversible inhibitor of 17 hydroxylase/C17,20-lyase (cytochrome P450c17 CYP17), a key enzyme required for testosterone synthesis, is being studied in a multicenter Phase 1/2 study in pre-pubescent children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modified-release Hydrocortisone Therapy as a Treatment for CAH
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
  • 批准号:
    10252568
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
Novel treatment approaches: sex steroid blockade in children
  • 批准号:
    10916862
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
海外基金